194 related articles for article (PubMed ID: 31579983)
1. CD133: An emerging prognostic factor and therapeutic target in colorectal cancer.
Akbari M; Shomali N; Faraji A; Shanehbandi D; Asadi M; Mokhtarzadeh A; Shabani A; Baradaran B
Cell Biol Int; 2020 Feb; 44(2):368-380. PubMed ID: 31579983
[TBL] [Abstract][Full Text] [Related]
2. The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.
Asadzadeh Z; Mansoori B; Mohammadi A; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Hemmat N; Derakhshani A; Brunetti O; Safaei S; Aghajani M; Najafi S; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 May; 137():111364. PubMed ID: 33592546
[TBL] [Abstract][Full Text] [Related]
3. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
[TBL] [Abstract][Full Text] [Related]
4. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
5. Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.
Ning ST; Lee SY; Wei MF; Peng CL; Lin SY; Tsai MH; Lee PC; Shih YH; Lin CY; Luo TY; Shieh MJ
ACS Appl Mater Interfaces; 2016 Jul; 8(28):17793-804. PubMed ID: 27348241
[TBL] [Abstract][Full Text] [Related]
6. A Validation Study of CD133 as a Reliable Marker for Identification of Colorectal Cancer Stem-Like Cells.
You CZ; Xu H; Zhao FS; Dou J
Bull Exp Biol Med; 2024 Jan; 176(3):369-375. PubMed ID: 38340198
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells.
Huang X; Huang J; Leng D; Yang S; Yao Q; Sun J; Hu J
World J Surg Oncol; 2017 Aug; 15(1):167. PubMed ID: 28854941
[TBL] [Abstract][Full Text] [Related]
8. Bufalin reverses multidrug resistance by regulating stemness through the CD133/nuclear factor-κB/MDR1 pathway in colorectal cancer.
Zhan Y; Qiu Y; Wang H; Wang Z; Xu J; Fan G; Xu J; Li W; Cao Y; Le VM; Ly HT; Yuan Z; Xu K; Yin P
Cancer Sci; 2020 May; 111(5):1619-1630. PubMed ID: 32058643
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy.
Feng Y; Gao S; Gao Y; Wang X; Chen Z
Oncotarget; 2016 Dec; 7(49):81402-81409. PubMed ID: 27833077
[TBL] [Abstract][Full Text] [Related]
10. Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond.
Soleimani A; Dadjoo P; Avan A; Soleimanpour S; Rajabian M; Ferns G; Ryzhikov M; Khazaei M; Hassanian SM
Life Sci; 2022 Mar; 293():120050. PubMed ID: 35026215
[TBL] [Abstract][Full Text] [Related]
11. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
Malkomes P; Lunger I; Luetticke A; Oppermann E; Haetscher N; Serve H; Holzer K; Bechstein WO; Rieger MA
Ann Surg Oncol; 2016 Sep; 23(9):2849-57. PubMed ID: 27059026
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.
Huang R; Wang G; Song Y; Tang Q; You Q; Liu Z; Chen Y; Zhang Q; Li J; Muhammand S; Wang X
Mol Med Rep; 2015 Aug; 12(2):2417-24. PubMed ID: 25936357
[TBL] [Abstract][Full Text] [Related]
13. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
[TBL] [Abstract][Full Text] [Related]
14. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
[TBL] [Abstract][Full Text] [Related]
15. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.
Zhao L; Yang Y; Zhou P; Ma H; Zhao X; He X; Wang T; Zhang J; Liu Y; Zhang T
J Immunother; 2015; 38(6):217-28. PubMed ID: 26049545
[TBL] [Abstract][Full Text] [Related]
17. CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype.
Paschall AV; Yang D; Lu C; Redd PS; Choi JH; Heaton CM; Lee JR; Nayak-Kapoor A; Liu K
Oncotarget; 2016 Nov; 7(48):78698-78712. PubMed ID: 27659530
[TBL] [Abstract][Full Text] [Related]
18. Effects of CD133 Silencing on Survival and Migration of HT-29 Colorectal Cancer Cells.
Akbari M; Shanehbandi D; Asadi M; Shomali N; Faraji A; Khaze V; Pakdel A; Mokhtarzadeh A; Ebrahimi AA; Shabani A; Bardaran B
Iran J Immunol; 2019 Sep; 16(3):246-257. PubMed ID: 31552833
[TBL] [Abstract][Full Text] [Related]
19. Proliferative Activity of Colorectal Cancer Cells with Different Levels of CD133 Expression.
Gisina AM; Kim YS; Potashnikova DM; Tvorogova AV; Yarygin KN; Lupatov AY
Bull Exp Biol Med; 2019 Aug; 167(4):541-545. PubMed ID: 31502129
[TBL] [Abstract][Full Text] [Related]
20. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.
Huang R; Mo D; Wu J; Ai H; Lu Y
Medicine (Baltimore); 2018 Jun; 97(23):e10446. PubMed ID: 29879012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
